Serum activin, gene expression, muscle mass and function in people with critical illness (SAGE-MUSCLE): an observational cohort study
Not Applicable
Completed
- Conditions
- Intensive Care Unit Aquired WeaknessPhysical Medicine / Rehabilitation - Physiotherapy
- Registration Number
- ACTRN12615000047594
- Lead Sponsor
- Footscray Hospital Western Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Have invasive mechanical ventilation for at least 48 hours and;
Are expected to be in ICU for at least 120 hours
Exclusion Criteria
Aged < 18;
They have a proven or suspected acute primary neurological process likely to result in global impairment of conscious level/cognition or prolonged weakness or;
Death is deemed imminent or inevitable.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum activin level[Daily until discharge from ICU];Needle muscle biopsy of the quadriceps with ultrasound guidance will be required to allow extraction of RNA. Target genes will be analysed by reverse transcription polymerase chain reaction (RT-PCR).[120 hours after admission to ICU];Six-Minute Walk test[On acute hospital discharge]
- Secondary Outcome Measures
Name Time Method Grip Strength measured with a hand held dynamometer.[On awakening; first standing occasion; discharge to ward and discharge from acute hospital.];Knee extension strength knee measured using Medical Research Council Scale for manual muscle testing.[On awakening; first standing occasion; discharge to ward and discharge from acute hospital.];Timed Up and Go Test.[On acute hospital discharge.];Physical Function in ICU test (PFIT)[On first standing occasion and on discharge to ward];Discharge destination[On discharge from acute hospital];ICU length of stay[On discharge from ICU];Hospital length of stay[On discharge from acute hospital]